ACACIA PHARMA LTD has a total of 114 patent applications. It decreased the IP activity by 23.0%. Its first patent ever was published in 2005. It filed its patents most often in United Kingdom, United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals are PHARMA TWO B LTD, CM & D PHARMA LTD and INNOLIFE CO LTD.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 22 | |
#2 | United States | 11 | |
#3 | EPO (European Patent Office) | 10 | |
#4 | Australia | 8 | |
#5 | China | 8 | |
#6 | WIPO (World Intellectual Property Organization) | 8 | |
#7 | Israel | 7 | |
#8 | Mexico | 7 | |
#9 | Canada | 6 | |
#10 | Republic of Korea | 6 | |
#11 | Brazil | 5 | |
#12 | Serbia | 4 | |
#13 | EAPO (Eurasian Patent Organization) | 3 | |
#14 | Hong Kong | 3 | |
#15 | New Zealand | 3 | |
#16 | Hungary | 1 | |
#17 | Japan | 1 | |
#18 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations |
# | Name | Total Patents |
---|---|---|
#1 | Gristwood Robert William | 73 |
#2 | Gilbert Julian Clive | 73 |
#3 | Fox Gabriel | 47 |
#4 | Cooper Nicola | 38 |
#5 | Wyllie Michael Grant | 14 |
#6 | Robert William Gristwood | 7 |
#7 | Julian Clive Gilbert | 7 |
#8 | Gabriel Fox | 7 |
#9 | Nicola Cooper | 3 |
#10 | Frodsham Michael | 2 |
Publication | Filing date | Title |
---|---|---|
GB202010361D0 | Therapy of post-operative nausea and vomiting | |
GB201720607D0 | Method | |
GB201702250D0 | Method | |
GB201618425D0 | method | |
AU2016216578A1 | The use of amisulpride as an anti-emetic | |
GB201506116D0 | Kit and combination therapy for nausea and vomiting | |
AU2014202535A1 | The use of amisulpride as an anti-emetic | |
GB201107533D0 | Formulaiton | |
NZ599880A | Use of bethanechol for treatment of xerostomia | |
GB201004445D0 | The treatment of salivary gland dysfunction | |
GB201004020D0 | New therapeutic use | |
GB0919822D0 | The treatment of salivary gland dysfunction | |
BRPI0810461A2 | Drug combination and its use in muscular loss treatment | |
GB0805292D0 | Pharmaceutical formulation | |
GB0714336D0 | new therapeutic use | |
GB0710981D0 | New Therapeutic use | |
GB0710979D0 | New Therapeutiv use | |
GB0710098D0 | New Therapeutic use | |
GB0710101D0 | New Therapeutic use | |
GB0710102D0 | New Therapeutic use |